Australia's largest stock trading and investment forum Australia's #1 stock forum

VLA

0.00%

$1.75 viralytics limited

Bioshares Report and Recommendation, page-2

First 2 Last

Share
Profile

Follow
DavieJones

245 Posts.

20

29/03/17

16:20

Post #: 23713734
Share

Originally posted by bripoz ↑

For those with access to the "Bioshares" publication, perhaps you can send a link to the full article.
I have received a copy and have cut and pasted the opening paragraph.... and the Summary.
Worth a read.... closing Recommendation has lifted from "Speculative Buy Class B... to Class A"

First para....
Viralytics (VLA: $1.025) is due to present data from clinical trials at the forthcoming AACR (American Association for Cancer Research) meeting in Washington DC on April 3 & 4 this year. Results from studies of Viralytics’ CAVATAK oncolytic cancer therapy will be discussed in two oral sessions and will be detailed in one poster session. These presentations can be regarded as high level......

...... Summary:-
Summary Release of new data at AACR will be a driver for increased interest in this stock, as will news of the company initiating additional Phase Ib studies or a decision to move into a pivotal study over the next 12 months.
Programs that may move into pivotal studies include the CAPRA, MITCI and Keynote-200 combination studies with Yervoy or Keytruda (in melanoma, NSCLC and metastatic bladder cancer). Other Phase Ib studies that the company may undertake include programs where Keytruda has approval, including head and neck cancer.
Viralytics is capitalised at $246 million. The company had $39.6 million in cash at the end of last year.
Bioshares recommendation: Speculative Buy Class A.

Expand

It's up on the VLA website now ...

https://www.viralytics.com/investor-centre/analysts-reports/analyst-coverage-2017/

.

VLA Price at posting: $1.04 Sentiment: Buy Disclosure: Held
8 Upvote

0 Great analysis

Reply

Top Stories

Capital raisings wrap: Brainchip, Ovanti, Lake and VHM

BGL

Bellevue aims for 45% production increase by FY 2028, announces $150M placement

MM1

Geochemical work at Newington picks up gold and copper anomalies for Midas

TRP

Tissue Repairs soars nearly 32% on TGA approval for wound healing gel

PEC

Perpetual sniffs TREOs beyond 4000ppm at Raptor play in Brazil